| Project/Area Number |
23659082
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
ISHIDA Tatsuhiro 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 准教授 (50325271)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIWADA Hiroshi 徳島大学, 大学院・へルスバイオサイエンス研究部, 教授 (50120184)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 薬物動態 / 代謝学 / ワクチン / アジュバント / リポソーム / DDS / PEG / 抗原デリバリー / ポリエチレングリコール / 免疫反応 |
|---|
| Research Abstract |
We showed that second dose PEGylated liposome is aggressively transported from marginal zone (MZ) into follicle in spleen when they are injected twice into the same rat with short interval1. We revealed that splenic MZ B cells capture and transport second dose liposomes into follicle in a time after second dose injection-dependent manner. The captured and then transported liposomes were finally taken up by follicular dendritic cell. We tried to apply this unique immune response to be a novel adjuvant system which enhances a specific antibody response against antigen encapsulated in second dose liposomes. Pre-immunization with low dose empty liposome, which triggers the transport of antigen-containing second dose liposomes into follicle, induced both anti-OVA IgM and anti-OVA IgG productions as OVA-containing liposomes, not free OVA, was intravenously injected as a second dose. The produced anti-OVA IgG contained IgG1, IgG2a and IgG2b subclasses. In addition, the high level of anti-OVA IgG lasted over 12 weeks after the immunization. These suggest that pre-stimulation with empty PEGylated liposomes could enhance the specific antibody response against antigen encapsulated in second dose liposomes. We conclude that our active transport methodology can be useful for a novel and alternative vaccine strategy to potentiate specific antibody response.
|
